- Home
- ICCM vs RFL Comparison
ICCM vs RFL Comparison
Compare ICCM & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- RFL
- Stock Information
- Founded
- ICCM 2006
- RFL 2017
- Country
- ICCM Israel
- RFL United States
- Employees
- ICCM N/A
- RFL N/A
- Industry
- ICCM
- RFL Real Estate
- Sector
- ICCM
- RFL Finance
- Exchange
- ICCM Nasdaq
- RFL Nasdaq
- Market Cap
- ICCM 59.9M
- RFL 67.7M
- IPO Year
- ICCM N/A
- RFL N/A
- Fundamental
- Price
- ICCM $1.05
- RFL $2.13
- Analyst Decision
- ICCM Strong Buy
- RFL
- Analyst Count
- ICCM 1
- RFL 0
- Target Price
- ICCM $2.50
- RFL N/A
- AVG Volume (30 Days)
- ICCM 347.5K
- RFL 313.2K
- Earning Date
- ICCM 08-19-2025
- RFL 06-11-2025
- Dividend Yield
- ICCM N/A
- RFL N/A
- EPS Growth
- ICCM N/A
- RFL N/A
- EPS
- ICCM N/A
- RFL N/A
- Revenue
- ICCM $3,273,000.00
- RFL $732,000.00
- Revenue This Year
- ICCM $83.41
- RFL N/A
- Revenue Next Year
- ICCM $185.02
- RFL N/A
- P/E Ratio
- ICCM N/A
- RFL N/A
- Revenue Growth
- ICCM 0.34
- RFL 35.56
- 52 Week Low
- ICCM $0.48
- RFL $1.27
- 52 Week High
- ICCM $1.66
- RFL $3.19
- Technical
- Relative Strength Index (RSI)
- ICCM 51.32
- RFL 61.68
- Support Level
- ICCM $0.96
- RFL $1.83
- Resistance Level
- ICCM $1.17
- RFL $2.04
- Average True Range (ATR)
- ICCM 0.08
- RFL 0.18
- MACD
- ICCM 0.01
- RFL 0.02
- Stochastic Oscillator
- ICCM 63.89
- RFL 55.44
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.